Bukwang Pharm. announced today completion of dosing in the proof-of-concept (PoC) phase IIa study of JM-010, a candidate for levodopa-induced dyskinesia (LID) in Parkinson’s disease patients. JM-010 was originally developed by Contera Pharma ApS, a CNS-focused Danish bioventure that is now a subsidiary of Bukwang Pharm.
LID occurs as an inevitable side effect in 60~70% of Parkinson’s disease patients receiving levodopa for a long-term treatment of the disease. JM-010 is a new drug candidate targeting this side effect and its PoC trial has been ongoing in South Africa. “Our plan now is to analyze the safety and efficacy data early next year, and start a pharmacokinetics study in Europe under IND straight afterwards. Within next year, we are aiming to enter phase 2,” Bukwang’s representative said.
Bukwang is strengthening its R&D activities with clinical developments of apatinib (anti-cancer) and MLR-1023 (anti-diabetic).
Bukwang’s representative added, “We are going to focus on finding growth engine for the company in the overseas market by innovative drug development, steering away from reliance on domestic market.”